Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.

Employees - 14, CEO - Daniel J. Hicklin, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -28.35, Piotroski Score(max is 10): 3, Working Capital: $15029000, Total Assets: $24155000, Retained Earnings: $-485272000, EBIT: -27047000, Total Liabilities: $7863000, Revenue: $21000000

AryaFin Target Price - $1.03 - Current Price $ - Analyst Target Price $